Patent ID: 11959143
Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 0:
1. A method for distinguishing melanoma cells from normal and dysplastic nevi cells in a skin lesion sample from a subject, comprising:
(a) amplifying nucleic acids from the skin lesion sample;
(b) assaying the expression level of one or more miRNAs in the skin lesion sample, wherein the one or more miRNAs comprise miR-339-5p, miR-15b, miR-572, miR-425, miR-1202, HBII-382_s, miR-1225-5p, miR-30c, miR-106b-star, miR-125a-5p, mgU6-53B, miR-25, miR-939, miR-92b-star, miR-500-star, miR-22, HBII-142_x, miR-181b, HBII-142, miR-663, miR-1224-5p, HBII-85-6_x, miR-1301, miR-345, miR-30a-star, ENSG00000202327, miR-92a, miR-127-3p, HBII-85-26, miR-31, miR-921, miR-146b-5p, miR-768-3p, miR-708, miR-139-5p, ACA24_x, miR-501-3p, or miR-502-3p;
(c) quantitatively comparing the levels of the one or more miRNAs in the skin sample as assayed in (a) to the levels of corresponding miRNA(s) in a normal skin or nevus reference sample; and
(d) identifying the skin lesion sample as containing:
(i) melanoma cells if the levels of the one or more miRNAs in the skin lesion sample differ from the normal skin or nevus reference sample, wherein the level of miR-339-5p, miR-15b, miR-425, miR-30c, miR-106b-star, miR-125a-5p, miR-25, miR-500-star, miR-22, miR-1301, miR-345, miR-30a-star, miR-181b, miR-92a, miR-127-3p, miR-31, miR-146b-5p, miR-708, miR-139-5p, ACA24_x, miR-501-3p, miR-502-3p are increased and the level of miR-572, miR-1202, HBII-382_s, miR-1225-5p, mgU6-53B, miR-939, miR-92b-star, HBII-142_x, HBII-142, miR-663, miR-1224-5p, HBII-85-6_x, ENSG00000202327, HBII-85-26, miR-921, miR-768-3p are decreased relative to the normal skin or nevus reference sample, or
(ii) not melanoma cells if the levels of the one or more miRNAs in the skin lesion sample do not differ from the normal skin or nevus reference sample.